On October 2, 2025, LENZ Therapeutics announced that its aceclidine‑based eye drop, VIZZ (1.44% aceclidine ophthalmic solution), is now commercially available in the United States. The company said that sample distribution to eye care professionals has already begun nationwide, and that commercial product shipments to consumers will start in October through an e‑pharmacy partner, with broader retail pharmacy availability expected by mid‑Q4 2025.
VIZZ is the first and only FDA‑approved aceclidine‑based eye drop for presbyopia, offering a rapid onset of near‑vision improvement—93% of participants in the Phase 3 CLARITY trial achieved 20/40 or better near vision within 30 minutes, with effects lasting up to 10 hours. The drug’s pupil‑selective mechanism provides a sub‑2 mm pinhole effect that extends depth of focus without inducing myopic shift, addressing the shortcomings of earlier pilocarpine‑based treatments.
The commercial launch marks a critical transition for LENZ, moving from regulatory approval to revenue generation. With a potential U.S. market of 128 million adults and a $3 billion+ addressable market, the availability of VIZZ positions the company to capture a significant share of presbyopia treatment. The announcement also signals the start of the company’s planned sales force rollout and e‑pharmacy distribution strategy, laying the groundwork for future sales momentum.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.